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Abstract  
Introduction: Hepatitis B virus (HBV) infection is the most important cause of hepatocellular 
carcinoma in sub-Saharan Africa (SSA). Although the tools to curb the epidemic are known, 
only a minority of HBV-infected persons are currently diagnosed and treated. 
Areas covered: We discuss HBV epidemiological trends in SSA, describe important 
determinants of its natural history, and summarize current knowledge on the continuum of 
HBV care. Using the results of a systematic review of the literature, we describe the 
proportion of patients with liver fibrosis at presentation for care. Throughout the manuscript, 
we highlight major research gaps and explore potential ways to improve uptake of HBV 
testing, evaluation of liver disease, access to antiviral therapy and monitoring of 
complications. 
Expert commentary: Less than 1% of HBV-infected individuals are diagnosed in SSA, 
despite the availability of rapid tests with good diagnostic accuracy. Up to 15% of individuals 
enter care with liver cirrhosis, a clear indication for antiviral therapy. Although the proportion 
of patients eligible for immediate antiviral treatment is generally below 20%, there are few 
published data from prospective cohort studies. The incidence of hepatocellular carcinoma 
could be reduced with improved access to antiviral therapy. 
 
 
Key words: hepatitis B virus; sub-Saharan Africa; liver cirrhosis, hepatocellular carcinoma, 
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1. Introduction 
Worldwide, hepatitis B virus (HBV) infection causes approximately 900,000 deaths per year 
and is the most important single risk factor for hepatocellular carcinoma (HCC)1. Whereas 
3.6% of the global population is affected by chronic HBV infection, defined as a single positive 
HBV surface antigen (HBsAg) by the World Health Organization (WHO)2, most countries in 
sub-Saharan Africa (SSA) have a prevalence above 8%2. In 2016, the World Health 
Assembly endorsed the Global Health Sector Strategy on viral hepatitis, calling for its 
elimination as a public health threat by 20303. In order to achieve this ambitious goal, the 
World Health Organization (WHO) estimates that new infections need to be reduced by 90% 
and hepatitis-related mortality by 65%. To guide the road to elimination and inform national 
hepatitis strategies, WHO has issued comprehensive guidelines for testing and management 
of HBV infection4,5. Furthermore, a list of specific objectives to be achieved by 2030 was 
established: 90% of infected persons need to be diagnosed, and 80% of eligible individuals 
treated3.  
In SSA, each step of the HBV continuum of care is severely affected by the lack of 
resources, awareness and political will (Figure 1). For instance, only 0.3% of the HBV-
infected persons have been diagnosed to date, despite the availability of cheap, highly 
sensitive HBsAg tests. Similar observations can be made about uptake of HBV treatment: 
the current standard of care for HBV therapy, tenofovir disoproxil fumarate (TDF), 
suppresses HBV replication in nearly all patients, is well-tolerated, and now increasingly 
available as a low-cost generic drugs. Yet, the proportion of HBV-infected individuals in need 
of antiviral therapy in SSA remains largely unknown, and access to treatment very limited. In 
addition, training of health-care workers on HBV management is insufficient: for example, in 
a recent survey conducted among a representative sample of physicians in Senegal, only 
51% of them knew that HBV vaccination was safe for newborns6. 
Generally, epidemiological and clinical research on HBV infection in SSA has been 
developing slowly and has so far not been able to attract appropriate funding. In this article, 
we review recent evidence on the determinants of the main components of the continuum of 
HBV care in SSA, from HBV testing to staging of liver disease, treatment and monitoring 
(Figure 1). We highlight the main scientific knowledge gaps and important challenges for the 
implementation of management strategies in order to guide further efforts in the field. 
Although the prevention of mother-to-child transmission and vaccination are cornerstones of 
the global strategy to eliminate HBV infection, we do not discuss HBV prevention aspects in 
this manuscript, but instead focus on the management of HBV-infected populations in SSA.  
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Whereas early studies suggested a high variation in HBV prevalence estimates between 
countries and sub-groups of the population in SSA, these findings can often be explained by 
methodological differences7-10. A recent meta-analysis of 44 studies in Cameroon highlighted 
the stability of HBV prevalence across different sub-populations, despite a certain degree of 
heterogeneity between studies. The overall pooled seroprevalence was 11.2% (95% CI 9.7-
12.8%), and the estimate remained above 10% after the exclusion of studies in populations 
previously considered as high-risk (10.6%, 95% CI 8.6-12.6%)11. In line with these findings, 
recent data from Senegal showed similar HBV prevalence estimates across different 
populations, including blood donors (17%), prison inmates (14%), military staff (14%) and 
HIV-infected persons (12%) 12-15. Considering the consistent results from recent studies 
across SSA, WHO now recommends HBsAg testing at least once in the general population 
of this region.  
 
Figure 2: Prevalence of chronic HBV infection in sub-Saharan Africa (adapted from 
Schweitzer et al.2) 
 
An estimated 2.7 million (interquartile range 1.8-3.9) of the 36.7 million persons living with 
HIV are co-infected with HBV, of whom 71% live in SSA16. HIV infection accelerates the 
progression of HBV-related liver disease and increases liver-related mortality17. In contrast to 
the situation in high-income countries, most persons acquire HBV during early childhood in 
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SSA, long before being infected with HIV. Therefore, HBV prevalence among HIV-infected 
individuals is generally similar to estimates from the general population18. In the past ten 
years, funding for research in SSA has been widely driven by efforts to fight HIV/AIDS, which 
explains the extensive body of literature on HBV determinants in HIV-infected populations, as 
opposed to the general population. Although many epidemiological parameters are 
comparable, considerations about the natural history and treatment outcomes of HIV/HBV-
coinfected persons can generally not be transferred to HIV-uninfected populations. 
 
2.2. HBV transmission and natural history 
In regions of low HBV endemicity such as Western Europe and North America, most 
infections occur in adolescents and young adults, mainly through sexual or percutaneous 
transmission19. By contrast, in SSA and Southeast Asia, the majority of HBV infections are 
acquired before the age of five. Perinatal transmission, which is most likely when HBV-
infected mothers have a high HBV viral load (VL) and a positive hepatitis B envelope antigen 
(HBeAg), predominates in Southeast Asia, whereas in SSA, children acquire HBV infection 
mainly through horizontal transmission from household contacts20,21. The proportion of 
HBeAg-positive pregnant women in SSA is generally lower than in Asia, varying between 1% 
in Ghana and 24% in Tanzania among HBV-monoinfected populations22-24 . However, the 
risk of perinatal transmission seems to be higher among HIV/HBV-coinfected mothers, who 
are twice as likely to be HBeAg-positive and three times more likely to have a high HBV VL 
compared to HIV-uninfected ones25. Sharing of cutting objects, such a razors, as well as 
other percutaneous injuries, including circumcision and scarification, are thought to account 
for the majority of HBV transmissions in SSA26. Even though sexual transmission of HBV 
infection does not seem to be of major importance in SSA, several reports have highlighted 
the potential for acquiring HBV through this route. Studies from Somalia and Ethiopia 
reported a higher HBV prevalence among adults compared to children, suggesting infections 
through sexual intercourse27,28. 
Several specificities of the natural history of HBV infection in SSA may have an impact on 
transmission, burden of disease and treatment outcomes. The risk for HBV infection of 
becoming chronic is inversely related to the age at infection. Ninety percent of those infected 
in the neonatal period develop chronic infection, whereas this is only the case for 20-50% of 
those infected during early childhood (<5 years), and for 5% of adults. Compared to Asian 
populations, HBV-infected individuals in SSA are more likely to become HBeAg-negative 
early in the course of disease (Figure 3): the yearly HBeAg-seroconversion rate is very high 
(14-16%) and only 10% are estimated to remain HBeAg-positive when reaching puberty29. As 
a result, most adults with a chronic HBV infection in the region are HBeAg-negative, 
generally with a low or undetectable HBV VL and no signs of liver inflammation 30. Early 
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Based on results from a community outreach program in the Gambia, the PROLIFICA 
(Prevention of Liver Fibrosis and Liver Cancer in Africa) study team showed that such a 
screen-and-treat strategy was feasible in SSA38. However, uptake of HBV testing outside of 
clinical and epidemiological studies has remained dramatically low in the region with less 
than 1% of HBV infections being currently diagnosed in Africa3. Even in clinical settings such 
as HIV outpatient clinics, where patients are linked to care, HBV testing rates remain very 
low. In a study of over 60,000 HIV-infected individuals from fifteen primary care clinics in 
Lusaka, Zambia, we showed that the uptake of HBV screening was slow and very different 
across clinical settings39. Furthermore, through the review of over 3,500 clinical charts from 
HIV clinics in ten African countries,  large differences in HBV screening uptake patterns 
across settings were observed, and the overall number of patients tested remained below 
25%40. These results are driven by financial constraints, as in many settings patients have to 
pay for diagnostic tests, but also by the lack of awareness and knowledge on HBV infection 
among health care workers. In Senegal, only 24% of physicians are aware of the existence 
of rapid diagnostic tests for detecting HBV infection6. 
The availability of rapid tests with decent diagnostic accuracy should help improve HBV 
diagnosis rates in the near future. For instance, the widely available point-of-care 
Determine® HBsAg test (Alere, USA) had an overall sensitivity of 87.9% in HIV-infected 
individuals in Zambia, when compared to the standard laboratory-based serological test, in 
line with results from a large, recently published meta-analysis41,42. Importantly, sensitivity 
was 95.9% among patients with a replicating HBV and 100% among those with a high HBV 
VL. Despite the fear that viral escape mutations might lead to false-negative HBsAg 
screening results, a study among HBV-infected individuals in Switzerland showed that 
specific resistance mutations associated with vaccine escape mutations did not affect the 
sensitivity of the test43. 
In order to significantly improve HBV testing rates in resource-limited countries, WHO 
recommends improving health-facility-based testing by systematically integrating HBV 
screening in established services such as antenatal and HIV outpatient clinics. In addition, 
innovative strategies to reach populations not linked to health-care, including vulnerable 
populations, will have to be adopted. Learning from previous experiences in community-
based HIV testing will be key to rapidly adapt and implement HBV-targeted testing 
interventions in SSA. For instance, in a large meta-analysis assessing the feasibility of 
community-based HIV testing strategies, Suthar et al. reported high rates of uptake and 
acceptability of interventions such as door-to-door, workplace or school-based testing, which 
could also be used to test for HBV infection44. As with HIV testing, specific interventions will 
have to be established for HBV testing in key populations.  
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3. Assessing HBV activity and degree of liver disease 
The initial evaluation of a subject with chronic HBV infection should include a complete 
history, a physical examination, the evaluation of blood markers (transaminases, HBV 
serological tests and VL), and the assessment of liver fibrosis/cirrhosis. Initiation of antiviral 
therapy is guided by the results of these parameters. A single determination of HBV 
replication and disease activity markers is generally insufficient to allow an immediate 
classification into one of the phases of disease (Figure 3). Serial measurements of serum 
HBsAg, HBV DNA and alanine aminotransferase (ALT) levels as well as liver fibrosis stage 
are required in most instances. Despite a complete assessment, some subjects fall into a 
grey area and management needs to be individualized. Additional routine investigations 
include liver ultrasonography for the periodic screening for HCC, and endoscopy for 
detecting esophageal varices in persons with cirrhosis. 
 
3.1. Liver inflammation 
Aminotransferase levels, which indicate the presence of liver inflammation, fluctuate over 
time, justifying the need for serial measurements for disease monitoring. Usually, ALT 
concentrations are higher than aspartate aminotransferase (AST) levels in chronic HBV 
infection, but with disease progression to cirrhosis, the AST/ALT ratio may be reversed. As 
transaminase measurements are widely available, including in primary care clinics across 
SSA, they are an essential part of determining disease activity in low-income countries and 
are included in all treatment guidelines. 
 
3.2. HBV replication 
In SSA, few facilities have the laboratory capacity for measuring HBV VL45. The price of 
commercial assays is high (generally over 50 USD per test), and their use requires specific 
infrastructure and skilled technicians. Serum HBV DNA concentrations assessed by real-time 
quantitative polymerase chain reaction is a strong predictor of the risk of developing HCC, 
and the value is used in the algorithm for deciding who to treat and how to monitor patients45. 
However, since it is measured very rarely in clinical routine in SSA, there is an urgent need 
for alternative ways to assess HBV replication. For instance, loop-mediated isothermal 
amplification (LAMP) is a promising new technology, which may soon allow the 
measurement of HBV VL at reduced cost and in very little time46. Furthermore, the 
measurement of HBV VL from dried blood spots has recently been validated in Zambia and 
will allow rural clinics in SSA to ship samples to reference labs without facing the need to 
secure the cold chain47. Few studies have assessed the proportion of treatment-naïve HBV-
Ac
ce
pte
d M
an
us
cri
pt
infected individuals with high replication in SSA. For example, Aberra et al. showed that in 
Ethiopia, only a small proportion (22%) of patients with chronic HBV infection had a VL 
>20,000 IU/ml, contrasting with results from a cohort of HIV/HBV-coinfected individuals 
starting antiretroviral therapy (ART) in Mozambique and Zambia, where 50% of the 
participants had an HBV VL >20,000 IU/ml48,49. Interestingly, in the latter study, all HBeAg-
positive patients had a high HBV VL, in line with observations made previously in Malawi50. 
This finding suggests that, in settings with limited access to HBV VL assays, a positive 
HBeAg test could be used as a proxy for a high HBV VL50.  
 
3.3. Fibrosis assessment 
Liver biopsy, the gold standard for assessing liver fibrosis, is not widely used in low-income 
countries as it involves high costs and dedicated infrastructure, relies on the skills of trained 
clinicians and pathologists, and carries the risk of complications and discomfort to the 
patient. Several non-invasive tests based on serum indices (AST-to-platelet ratio index 
[APRI], FIB-4) or ultrasound principles (transient elastography [TE]) have been developed to 
replace liver biopsy for the assessment of liver disease stage. TE is currently the best 
alternative to liver biopsy, as it has showed excellent accuracy for quantifying liver fibrosis 
and cirrhosis in HBV-infected patients36,51-53, and can be used in outpatient or community 
settings by non-specialist health-care staff. Unfortunately, the cost of the TE device has 
limited its widespread use in resource-limited settings. If TE is unavailable, WHO 
recommends the use of the APRI score, which is based on the measurement of laboratory 
tests readily available in resource-limited settings54. Although APRI has a high specificity for 
the detection of liver cirrhosis, its low sensitivity for detecting significant fibrosis and cirrhosis 
at the specified cut-off ranges causes many patients with advanced fibrosis and cirrhosis to 
be missed55.  
Although the presence of liver cirrhosis is a clear indication for immediate HBV therapy, few 
studies have reported on the degree of liver fibrosis in treatment-naïve HBV-infected 
individuals in SSA to date. In addition, study design, sample size and methods to assess liver 
fibrosis are highly variable across publications. Figure 4 shows the proportion of HBV-
infected individuals with significant fibrosis or cirrhosis from a systematic review of studies 
that have assessed these parameters in SSA. Six studies including 1,089 patients reported 
data on fibrosis/cirrhosis in HBV-moninfected patients and 10 studies including 629 patients 
among HIV/HBV-coinfected patients. Fibrosis assessment was performed with APRI in eight 
studies, TE in five studies, and FIB-4 and Fibrotest each in one study. The prevalence of liver 
cirrhosis ranged from 0.3% to 17% in HBV-monoinfected and from 4% to 14% in HIV/HBV-
coinfected individuals. In HBV-monoinfected patients, the proportion with significant fibrosis 
varied between 4% and 30%, whereas in HIV/HBV-coinfected ones, estimates seemed to be 
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higher, with a range between 12% and 46%. Heterogeneity in results probably reflect 
differences between the settings in which the studies were performed. For instance, Aberra 
et al. found a very high prevalence of liver cirrhosis (17.2%) among HBV-moninfected 
individuals in a hospital-based cohort, whereas Shimakawa et al. found a prevalence of 
cirrhosis <1% in a rural community-based cohort, which is probably more representative of 
the general population30,55.  
 
Figure 4: Proportion of HBV-infected individuals with significant fibrosis and cirrhosis, by 
HIV-infection status (systematic review of the literature performed on 27th November 2017) 
 
 
4. Treatment eligibility, access and outcomes 
The goal of HBV therapy is to improve survival and quality of life by preventing the 
progression of liver disease and, consequently, the development of HCC. Furthermore, 
antiviral therapy helps prevent HBV reactivation and mother-to-child transmission, as well as 
to treat HBV-associated extrahepatic manifestations. The decision to initiate antiviral therapy 
is usually based on the combined assessment of HBV replication (HBV VL), inflammation 
(ALT), and stage of liver fibrosis. Several international guidelines, including by WHO, give 
recommendations on HBV management, but the optimal timing and indications for treatment 
are still debated35,56,57. In general, treatment is targeted at persons with chronic HBV infection 
who are at high risk of disease progression and HCC: those with moderate or severe liver 
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inflammation, and/or fibrosis and high viral replication. The benefits of treatment of HBV-
infected individuals with mild inflammation or fibrosis are uncertain. As only very limited long-
term data are available from SSA, it is unknown if the impact of antiviral therapy on disease 
progression is similar compared to other regions.  
 
4.1. Treatment indication 
WHO recently issued HBV treatment recommendations based on other international 
guidelines, but including algorithms for resource-limited settings without access to all 
necessary diagnostic tools5. Currently, it is recommended to treat all adults, adolescents and 
children with chronic HBV infection and evidence of cirrhosis (based on clinical signs, TE or 
APRI score), regardless of ALT levels, HBeAg status or HBV VL. Treatment is also 
recommended for non-cirrhotic adults with chronic HBV infection aged more than 30 years 
with persistently abnormal ALT levels and evidence of high-level HBV replication (HBV DNA 
>20,000 IU/mL). Where HBV VL testing is unavailable, treatment may be considered based 
on persistently abnormal ALT levels alone. Furthermore, all HIV/HBV-coinfected individuals 
should receive TDF-containing ART, independent of CD4 count or stage of liver disease58. 
Continued monitoring is necessary in all persons with a chronic HBV infection, particularly if 
they do not yet meet the criteria for initiating antiviral therapy. 
One of the main research gaps in the field of HBV care in SSA is the lack of prospective 
cohort data on treatment eligibility. As shown in Figure 4, only three published studies 
assessed the proportion of HBV-monoinfected patients with cirrhosis using TE, including a 
total of 677 individuals. In community-based studies from West Africa, between 2% and 10% 
of patients were eligible for antiviral therapy according to WHO guidelines38,59. In contrast, a 
hospital-based study from Ethiopia found a much higher proportion, with approximately one 
quarter of patients having an indication to start treatment55. Importantly, the study by Jaquet 
et al. highlights the need for prospective studies of patients without an immediate indication 
for therapy as nearly 50% of the participants had some degree of HBV-related disease 
activity, which warranted follow-up measurements59. In summary, there is an alarming 
paucity of data available on HBV treatment needs in SSA, which is essential information for 
the planning of resource allocation to fight the global HBV epidemic.  
 
4.2. Treatment options and outcomes 
In high-income countries, two distinct HBV treatment modalities have been commonly used: 
1) pegylated interferon (pegIFN), which, given as weekly injections for ≥12 months, has the 
potential to achieve HBV functional cure, but is expensive and leads to severe side-effects, 
and 2) nucleoside analogues (NUC), which are well tolerated but require lifelong therapy in 
most patients. TDF is currently the NUC of choice as it is very effective in achieving an 
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undetectable HBV VL as well as the normalization of ALT levels, and has few side-effects. 
Unlike with other NUC such as lamivudine or entecavir, the development of HBV resistance 
to TDF has not yet been documented in clinical studies. Lately, tenofovir alafenamide 
fumarate (TAF), a prodrug of tenofovir that enables enhanced delivery of the parent 
nucleotide and its active diphosphate metabolite into lymphoid cells and hepatocytes, was 
shown to be non-inferior to TDF for the treatment of HBV infection, while being associated 
with a lower risk of developing nephrotoxicity or osteopenia60. However, TAF is generally not 
yet available in SSA. 
Suppression of HBV replication 
with TDF reduces the degree of 
chronic liver inflammation and 
leads to the regression of liver 
fibrosis61. In SSA, several 
observational studies have 
shown excellent rates of HBV 
suppression in cohorts of HIV-
infected individuals, and rates 
of HBsAg loss appear to be 
higher than among HBV-
monoinfected patients62,63. 
Furthermore, a significant 
proportion of HIV/HBV-
coinfected individuals started on 
TDF-containing ART in Zambia 
showed a regression in liver 
fibrosis stage after one year of 
therapy62. Finally, TDF is also beneficial in reducing the incidence of HCC among HBV-
infected populations64, but similar studies have not yet been performed in African settings, 
where other HCC risk factors such as aflatoxin and alcohol consumption are prevalent.  
 
4.3. Treatment access 
Few African countries have developed national treatment strategies for the management of 
chronic HBV infection65. Although TDF is now part of first-line ART for HIV infection in most 
resource-limited countries, access to this drug for HBV-monoinfected individuals has 
remained severely restricted. However, several countries in SSA have recently made 
important steps towards the access to generic TDF for all HBV-infected individuals in need of 
therapy. Often, the determination and commitment of dedicated physicians and members of 
Box 1. Access to HBV therapy in Senegal 
After having been confronted with difficulties in the care of 
HBV-infected individuals for many years, members of the 
Senegalese Society of Gastroenterology (SOSEGH) 
approached the National AIDS program to discuss a 
potential collaboration in 2006. The latter offered to make 
lamivudine available for HBV-infected individuals in need of 
treatment in Dakar, the capital city. As TDF became available 
for HIV-infected individuals in 2010, HBV-infected persons 
also received access to this new drug, again through the 
National AIDS program. However, stock-outs were common, 
so that many physicians had to switch patients back to 
lamivudine to guarantee the continuity of their treatment. 
After several years of discussion with the SOSEGH, the 
Senegalese Ministry of Health agreed to provide TDF for the 
treatment of HBV infection in early 2017. Generic TDF is 
now available for HBV-infected patients at a reduced price 
of approximately 10 USD per month at four main hospitals 
in Dakar. Stock-outs still occur, but their frequency could be 
reduced if generic drugs were made available to public 
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the civil society were crucial in this process, as exemplified by the situation in Senegal (Box 
1). 
 
4.4 Complications and co-morbidities 
The main complications of chronic HBV infection are the development of liver cirrhosis and 
HCC. According to the few cross-sectional studies available from SSA, up to 17% of HBV-
infected patients present for care with liver cirrhosis (Figure 4). However, data on the risk of 
liver decompensation in these patients are scarce. In a recent clinical survey of patients 
hospitalized with signs of liver decompensation in Uganda, one quarter had a chronic HBV 
infection and the main complication of cirrhosis was the development of ascites66. 
Over 50% of cases of HCC can be attributed to HBV infection in SSA, whereas 22% of them 
are HBV-related in Europe67. Large observational studies from Asia showed that HBV-related 
HCC incidence was strongly associated with the presence of cirrhosis, high HBV VL, 
genotype, and HBeAg-seropositivity68-70. However, data on HCC from SSA are poor and 
generally limited to case-control studies71,72. In one of few longitudinal studies assessing the 
incidence of HBV-related HCC in SSA, Shimakawa et al. reported an incidence of 56 cases 
per 100,000 person-years among 405 chronic carriers, with a median follow-up of 28 years in 
the Gambia30.  
Most studies comparing the risk of HCC between patients on potent NUC and matched 
untreated controls found a significant risk reduction with NUC therapy but the overall risk was 
not eliminated73. Unlike the natural history of HCV-related HCC, which is driven by liver 
cirrhosis, HBV-related HCC also develops in non-cirrhotics, which makes surveillance 
strategies more complex74. Because of the potential synergistic carcinogenic interaction 
between aflatoxin B1, a fungal toxin which often contaminates foodstuffs in SSA, and HBV, 
patients of African origin are thought to be more likely to develop HCC at a young age75. 
However, this observation has been much debated and could be explained by the specific 
age distribution of the general population76. The systematic screening for HCC aims at 
reducing mortality by diagnosing small lesions that are potentially curable by resection, 
ablation or transplantation. However, he need for HCC surveillance in non-cirrhotic patients 
successfully treated with TDF is debated. Thus, HBV-related HCC surveillance programs in 
SSA would benefit from a risk score to help clinicians target groups of individuals most at risk 
of developing an HCC. Unfortunately, management capacity of HBV-related complications 
are currently limited in SSA, except from a few large teaching hospitals.  
Besides the synergistic effect of HIV infection on the development of HBV-related liver 
complications (see above), hepatitis delta virus (HDV) infection is an additional HCC risk 
factor. In a recent study from the Swiss HIV Cohort Study, HIV/HBV/HDV-coinfected 
individuals were nine times more likely to develop an HCC compared to their HDV-uninfected 
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counterparts77. Currently, there are still uncertainties about the epidemiology of HDV infection 
in SSA. According to a recently published meta-analysis, the proportion of HBV-infected 
individuals with an HDV coinfection ranges from 0.1% in southern Africa to 25.6% in central 
Africa78. Thus, estimates vary widely across regions and sometimes even within countries, 
which underlines the need to better understand the contribution of HDV infection to the 
burden of HCC in SSA.  
 
5. Conclusion 
The availability of good diagnostic tests and potent antiviral therapy, as well as the fast-
growing pipeline of drugs expected to help achieve HBV functional cure, have led WHO and 
other stakeholders to set HBV elimination by 2030 as a major global health target. However, 
current levels of dedication and funding to fill the many related research gaps are insufficient 
to reach this goal. In particular, knowledge about the main epidemiological and clinical 
determinants of HBV infection in SSA is still very limited. In order to inform the design and 
implementation of public health strategies, there is an urgent need for dedicated, long-term 
cohort studies aiming at understanding the natural history and treatment outcomes of HBV-
infected individuals in the region. 
HBV-related mortality will continue to increase if measures to improve its management in 
resource-limited countries are not taken rapidly. International recommendations now clearly 
stipulate the need for HBV screening of the general population in SSA, which should be 
facilitated by the widespread availability of rapid HBsAg tests. Tools to assess individual 
treatment eligibility at low cost, including the evaluation of liver fibrosis and viral replication 
need to be developed and validated in the region. Although access to TDF for the treatment 
of chronic hepatitis B seems to improve slowly, efforts from health authorities and policy 
makers will be crucial to allow proper management of HBV infection for all people infected 
and, eventually, achieve the global elimination of the infection.  
 
6. Expert commentary 
Eliminating viral hepatitis as a major public health problem by 2030 must be our common 
goal. According to WHO, HBV testing has to increase from less than 1% to 80% in sub-
Saharan Africa (SSA) if that ambitious target is to be met. This is very challenging, 
considering that current rates of routine HBV testing are very poor, even in health-care 
settings such as HIV clinics, where HBV screening has been recommended for years. Thus, 
major efforts are necessary to increase HBV testing uptake in established clinical structures, 
and to evaluate novel, acceptable community-based testing strategies. Recent experiences 
in the field of HIV testing in SSA should be a source of inspiration for the design of such 
programs. As low rates of HBV testing are mainly due to insufficient awareness and financial 
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resources, existing point-of-care tests with good diagnostic accuracy are to be made widely 
available across SSA.  
Obviously, diagnosing HBV infections is only the first step in the continuum of HBV care. The 
measurement of HBV viral load (VL) and the assessment of the degree of liver fibrosis are 
cornerstones of HBV management. Currently, access to optimal diagnostic tools, such as 
HBV amplification assays and transient elastography, is limited by their high costs. Although 
several non-invasive serological scores for the assessment of liver fibrosis have been 
validated in different settings, they generally have a poor diagnostic accuracy. For instance, 
the test currently recommended by WHO, the APRI score, fails to detect the majority of 
cases of liver cirrhosis. Therefore, advances in the development of affordable point-of-care 
HBV VL assays as well as tools to assess liver fibrosis are urgently needed. 
Fortunately, access to generic tenofovir, the mainstay of HBV-therapy, is becoming a reality 
in an increasing number of clinical settings in low-income countries. Although the proportion 
of individuals with an indication for therapy in SSA remains to be determined, there is 
emerging evidence on the benefits of antiviral therapy on HBV-related clinical outcomes, 
including the improvement of liver fibrosis and the reduction of the incidence of 
hepatocellular carcinoma. However, the lack of long-term prospective cohorts dedicated to 
the study of HBV-related outcomes in SSA represents one of the major current research 
gaps. Considering the number of antiviral drugs with the potential for achieving the functional 
cure of HBV infection currently in the pipeline, a better understanding of the main 
determinants of HBV infection and its complications is urgent. Therefore, increased funding 
for HBV research in SSA needs to be advocated for. 
In summary, the tools needed to diagnose and evaluate HBV infection, as well as antiviral 
therapy to suppress its replication are well established. However, most current diagnostic 
methods are either too expensive to be rolled out at a large scale in SSA, not validated, or 
not accurate enough. As the functional cure of HBV infection is becoming a realistic goal with 
future treatment modalities, dedicated research cohorts are needed to inform future needs of 
African healthcare programs so that strategies for the elimination of HBV infection can be 
tailored to specific settings. 
 
7. Five-year view 
In order to achieve HBV elimination, the natural history of HBV and treatment outcomes will 
have to be evaluated in dedicated research cohorts in SSA, which will be established in 
parallel to the upscale of HBV care interventions. Both the scientific community as well as 
policy makers will depend on findings from such studies to design sound public health 
interventions. The implementation of specific community-based testing strategies, adapted to 
the local contexts, will be evaluated and will lead to the establishment of cost-effective 
Ac
ce
pte
d M
an
us
cri
pt
screening programs and successful linkage to care of patients diagnosed. Finally, validated 
point-of-care tests will allow the measurement of HBV VL and adapted fibrosis scores will 
help clinicians in deciding who should be treated and how patients should be monitored. 
However, despite the improved access to diagnostic tools and antiviral therapy, the 
implementation of general HBV testing as well as linkage to and retention in care will remain 
a challenge, as observed since many years in the fight against HIV/AIDS. 
The first phase 2 trials evaluating combinations of newer drugs with the prospect of achieving 
the functional cure of a majority of HBV-infected individuals will be underway within the next 
five years. These novel treatment modalities are expected to allow a finite duration of 
treatment, which will, in the end, also reduce the financial burden of HBV management on 
national health systems. As the functional cure of HBV infection has been shown to lower the 
incidence of HCC, it can be expected that the rate of HBV-related complications will also 
decrease with time. 
 
Key issues 
- HBV infection is the most important cause of liver cirrhosis and hepatocellular 
carcinoma in sub-Saharan Africa (SSA). 
- To achieve HBV elimination as a major public health issue by 2030, the proportion of 
individuals tested needs to reach 90% and those treated 80%.   
- Currently, less than 1% of HBV-infected individuals are diagnosed in SSA and access 
to antiviral therapy remains limited. 
- Between 1% and 17% of HBV-infected individuals in SSA present with liver cirrhosis, 
depending on the clinical setting. 
- Prospective cohorts aiming at the long-term assessment of treatment eligibility and 
outcomes, as well as the evaluation of the incidence and risk factors of hepatocellular 
carcinoma are urgently needed in SSA. 
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